A Phase II Study of Bevacizumab, Irinotecan, and Temozolomide for Relapsed or Refractory Neuroblastoma

Protocol
10-015
Full Title
Combination of Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma: A Phase II Study
Phase
II
Purpose

The purpose of this study is to evaluate a combination of three anticancer drugs — irinotecan, temozolomide, and bevacizumab — in patients with neuroblastoma that has returned or is no longer responding to standard therapies.

Irinotecan and temozolomide are two drugs that have been used together to treat neuroblastoma. Bevacizumab is not approved for neuroblastoma, but is used to treat advanced colorectal, lung, breast, kidney, and brain cancers.

Bevacizumab works by blocking vascular endothelial growth factor (VEGF), a protein that promotes the growth of tumor cells and blood vessels in and around tumors. It has been used with irinotecan before to treat cancer, but not in children with neuroblastoma.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a confirmed diagnosis of neuroblastoma that has returned or is no longer responding to standard therapies.
  • At least 3 weeks must have passed since completion of prior therapy (2 weeks since biologic therapy) and entry into the study.
  • This study is open to patients of all ages.

For more information about this study and to inquire about eligibility, please contact Dr. Shakeel Modak at 212-639-7623.

Disease(s)
Neuroblastoma
Locations
Related Diseases